Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29 2022 - 4:01PM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to breaking through barriers in gene therapy and
neurology, has entered into an employment agreement with a newly
hired employee that, among other things, provides for the grant to
such employee of a non-qualified stock option and restricted stock
units as an inducement material to such employee’s entering into
employment with Voyager. The inducement awards were approved by the
Compensation Committee of Voyager’s Board of Directors in
accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The
option award became effective on November 28, 2022, and the
restricted stock unit award is scheduled to become effective on
January 1, 2023.
The stock option award provides for the purchase of an aggregate
of 54,000 shares of Voyager’s common stock, and the restricted
stock unit award will represent 27,000 shares of Voyager’s common
stock. The stock option has a ten-year term and an exercise price
of $5.57 per share, which is equal to the closing price of
Voyager's common stock on November 28, 2022, the effective date of
grant. The stock option vests over four years, with 25% of the
shares underlying the stock option vesting on the first anniversary
of the effective date of grant and 75% of the shares underlying the
stock option vesting in 36 equal monthly installments following the
first anniversary of the effective date of grant. The restricted
stock unit award vests annually in equal installments over three
years, beginning on the first anniversary of the effective date of
grant. Vesting of the equity awards is subject to the employee’s
continued employment with Voyager. Each equity award is also
subject to the terms and conditions of an award agreement.
About Voyager Therapeutics Voyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to
breaking through barriers in gene therapy and neurology. The
potential of both disciplines has been constrained by delivery
challenges; Voyager is leveraging cutting-edge expertise in capsid
discovery and deep neuropharmacology capabilities to address these
constraints. Voyager’s TRACER AAV capsid discovery platform has
generated novel capsids with high target delivery and blood-brain
barrier penetration at low doses, potentially addressing the narrow
therapeutic window associated with conventional gene therapy
delivery vectors. This platform is fueling alliances with Pfizer
Inc., Novartis Pharma AG and Neurocrine Biosciences, Inc. as well
as multiple programs in Voyager’s own pipeline. Voyager’s pipeline
includes preclinical programs in Parkinson’s disease, Alzheimer’s
disease, and amyotrophic lateral sclerosis (ALS), each with
validated targets and biomarkers to enable a path to rapid
potential proof-of-biology. For more information, visit
www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and
TRACER™ is a trademark, of Voyager Therapeutics, Inc.
InvestorsInvestors@vygr.com
MediaPeg
Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024